Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.trecan.2015.10.002 http://scihub22266oqcxt.onion/10.1016/j.trecan.2015.10.002 C4746004!4746004!26870836     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Trends+Cancer 2015 ; 1 (3): 161-73 Nephropedia Template TP {{tp|p=26870836|t=2015. Collateral Lethality: A new therapeutic strategy in oncology |pdf=|usr=}}{{26870836}} gab.com Text Collateral Lethality: A new therapeutic strategy in oncology JO: Trends Cancer http://www.kidney.de/pget.php?&tw=1&pmid=26870836 #FOAvip Genomic deletion of tumor suppressor genes (TSG) is a rite of passage for virtually all human cancers. The synthetic lethal paradigm has provided a framework for the development of molecular targeted therapeutics that are functionally linked to the loss of specific TSG functions. In the course of genomic events that delete TSGs, a large number of genes with no apparent direct role in tumor promotion also sustain deletion as a result of chromosomal proximity to the target TSG. In this perspective, we review the novel concept of ?collateral lethality?, which has served to identify cancer-specific therapeutic vulnerabilities resulting from co-deletion of passenger genes neighboring TSG. The large number of collaterally deleted genes, playing diverse functions in cell homeostasis, offers a rich repertoire of pharmacologically targetable vulnerabilities presenting novel opportunities for the development of personalized anti-neoplastic therapies. Twit Text FOAVip Collateral Lethality: A new therapeutic strategy in oncology ????Trends Cancer http://www.kidney.de/pget.php?&tw=1&pmid=26870836 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26870836 #FOAvip English Wikipedia <ref>{{Cite pmid|26870836}}</ref> Collateral Lethality: A new therapeutic strategy in oncology #MMPMID26870836 Muller FL; Aquilanti EA; DePinho RA Trends Cancer 2015[Nov]; 1 (3): 161-73 PMID26870836show ga Genomic deletion of tumor suppressor genes (TSG) is a rite of passage for virtually all human cancers. The synthetic lethal paradigm has provided a framework for the development of molecular targeted therapeutics that are functionally linked to the loss of specific TSG functions. In the course of genomic events that delete TSGs, a large number of genes with no apparent direct role in tumor promotion also sustain deletion as a result of chromosomal proximity to the target TSG. In this perspective, we review the novel concept of ?collateral lethality?, which has served to identify cancer-specific therapeutic vulnerabilities resulting from co-deletion of passenger genes neighboring TSG. The large number of collaterally deleted genes, playing diverse functions in cell homeostasis, offers a rich repertoire of pharmacologically targetable vulnerabilities presenting novel opportunities for the development of personalized anti-neoplastic therapies. äCollateral Lethality: A new therapeutic strategy in oncology (epmc).pdf DeepDyve Pubget Overpricing